Clinical Trial

Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-lable phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor activity of CMAB017 in advanced malignant solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-10.
Status change: Not Yet Recruiting → Recruiting 2025-09-09
Trial Details
NCT Number NCT06933069
Lead Sponsor Taizhou Mabtech Pharmaceutical Co.,Ltd
Conditions Solid Malignancies
Enrollment 55 participants
Start Date 2025-06-09
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-11